Companies

WeWeb is a visual programming tool that allows you to build user interfaces on top of existing databases & auth systems. It allies the short learning curve of no-code with the freedom of code. CONTROL & FREEDOM – Build pixel-perfect frontends with drag-and-drop UI elements and no-code CSS properties but have the option to add custom code or import your own Vue.js components. CODE BEST PRACTICES – Follow development best practices by building components, global workflows and re-usable functions with no-code triggers and formulas with the option to add custom JS where needed. NO VENDOR LOCK-IN – WeWeb generates a standard PWA-ready Single Page Application and allows you to deploy your projects on your own infrastructure. Build in no-code, host on-premise.

Asterisk (asterisk.so) is an AI Hacker for Codebases - it automatically finds, verifies, and patches security vulnerabilities in codebases, just like a human security engineer would. Asterisk can find business logic errors with context-aware scanning and automate the full auditing cycle to generate reports with near-zero false positives. Asterisk has autonomously discovered vulnerabilities in Google, Hoppscotch, and others.

We're building a commerce solution for SaaS companies globally that have overseas customers. We especially help them with streamlining billing operations like invoicing and reconciliation, managing foreign sales tax and accepting payments. We abstract out the complexities of compliance, remittance and integration for these merchants by running all that machinery in the background.

We are building a collections and reconciliation platform for MSME's in India. In India, reconciliation is largely manual and error prone due requiring manual matching of bank statements with Invoices. In my last role, I used to head product for PayU, India #1 Fintech firm. I would love to connect with other Fintech founders building solving similar problems and in the neobanking space

YearEnd helps startup employees optimize their equity and taxes, and can also file their tax returns. They simply connect their financial accounts and YearEnd will tell them how much tax they’ll owe and will make recommendations on how to make better decisions. At the end of the year, YearEnd can also file their tax return for them or they can collaborate with their existing tax accountant.

zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic. Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications.

UX teams are scaling exponentially, but in order to scale effectively, they need to be able to reuse each other’s work. The problem is that right now, UX designers and developers don’t know what’s been done before and they end up rebuilding the same things – over and over. zeroheight integrates with UX tools and allows teams to document their work, so that it can be reused and they can deliver UX faster.

Angstrom AI builds GenAI-based molecular simulations to substitute wet lab experiments in the pre-clinical drug development pipeline. We are a team of 2 PhD's and 2 Professors from the University of Cambridge who decided to start a company together after we realised how to combine breakthoughs in our research in quantum-accurate models of physics and generative AI models. Our Biotech/Pharma clients can verify the efficacy and safety of new drug candidates using our computer simulations, which match the accuracy of wet lab experiments, but are over 100x faster. We achieve this accuracy by constraining our genAI-based simulations to obey the laws of physics, avoiding the hallucinations seen in other GenAI technologies. Since joining YC, Angstrom AI has developed the first physically accurate gen-AI based simulation of multiple molecules interacting. We have published the first molecule water solubility results with accuracy within the error range of wet lab experiments. We have also kicked-off a 150K pilot project with a pharma company to apply our tech to estimating solubility in their drug development pipeline.


